Drugs / MLN3126
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02209506 | Jul → Sep 2014 | — | Takeda | Terminated | No outcome recorded |
| Phase 1 | NCT02447458 | Sep 2013 → Jan 2014 | — | Takeda | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MLN3126 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02447458 ↗ |
| Action | Inhibit | “C-C chemokine receptor type 9 antagonist” CHEMBL3545268 ↗ |
| Route | Oral | “administered orally as tablets” NCT02209506 ↗ |
| Target | CCR9 | “C-C chemokine receptor type 9 antagonist” CHEMBL3545268 ↗ |